atomoxetine / Generic mfg. - LARVOL DELTA

An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system. (PubMed, Sci Rep) - "Our analysis revealed potential associations between various drugs and mental disorders, with isotretinoin, montelukast, risperidone, methylphenidate, atomoxetine and antidepressants showing higher ROR values, indicating a possible risk of mental disorders. Additionally, we found that some drugs did not explicitly list the risk of mental disorders in their instructions for use."

Adverse events • Journal • Acne Vulgaris • ADHD (Impulsive Aggression) • Allergy • Asthma • Attention Deficit Hyperactivity Disorder • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Mental Retardation • Narcolepsy • Psychiatry • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

The promoting effects of digital targeted cognitive training in medication treatment for children with ADHD: a randomized controlled trial. (PubMed, BMC Med) - P=N/A | "These findings demonstrated that, in comparison to medication monotherapy, the TCT + M treatment did not lead to more improvements in the core symptoms of ADHD, nor did it show superiority in other secondary outcomes. Specifically in children treated with atomoxetine, there's a potential promoting effect of targeted cognitive training on medication treatment in terms of the alleviation of ADHD core symptoms."

Clinical • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

Long term safety of ADHD medication in patients with schizophrenia spectrum disorders. (PubMed, Mol Psychiatry) - "Atomoxetine was associated with a reduced risk of hospitalization for psychosis (aHR = 0.87 [0.78-0.98]), lisdexamphetamine with a reduced risk of somatic hospitalizations (aHR = 0.70 [0.58-0.84]), and ADHD polytherapy with an increased risk of somatic hospitalizations (aHR = 1.37 [1.07-1.74]). In conclusion, we find that for people with SSDs, the use of ADHD medication (particularly lisdexamphetamine in all dosages and long-acting methylphenidate in low to medium doses) is safer than generally conceived. The benefits of its use for patients with SSD and comorbid ADHD should therefore be weighed against the risks in a shared decision-making process aimed at improving patients' chances of recovery."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Psychiatry • Schizophrenia

Effect of catecholaminergic neuromodulation on slow brain travelling waves (OHBM 2025) - "Participants underwent atomoxetine or placebo administration following a double-blind, counter-balanced design... Our results suggest that neuromodulatory tone affects travelling wave propagation, and that this arousal-modulated propagation shapes integrated functional connectivity features, highlighting specific effects of prolonged and transient neuromodulatory influences on slow brain dynamics. Novel Imaging Acquisition BOLD fMRI 1 Physiology, Metabolism and Neurotransmission: Pharmacology and Neurotransmission 2"

CNS Disorders

Neuromodulatory effects on brain traveling waves: Insights from combined pharmacology, pupillometry and fMRI (OHBM 2025) - "Specifically, I assessed the effect of atomoxetine, which increases the levels of noradrenaline and dopamine in the brain (N = 36), and the effect of lysergic acid diethylamide (LSD), a serotoninergic agonist (N = 15)...Furthermore, pupil signatures indicated that instantaneous changes in neuromodulatory activity may act as time-specific regulators of travelling wave activity. The findings highlight specific effects of both prolonged and transient neuromodulatory influences on slow brain dynamics, suggesting a finely tuned regulation of brain communication at the slow time scales."

CNS Disorders

Selective Laser Sintering of Atomoxetine Tablets: An Innovative Approach for Small-Scale, Personalized Production. (PubMed, Pharmaceutics) - " SLS printing is a viable alternative to traditional tablet manufacturing, offering control over drug release profiles through parameter adjustment. The technique supports the development of high-quality, patient-specific dosage forms and shows promise for broader implementation in personalized pharmaceutical therapy."

Journal

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms (clinicaltrials.gov) - P=N/A | N=29 | Recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Oct 2025 ➔ Oct 2027 | Trial primary completion date: Jun 2025 ➔ Jun 2027

Trial completion date • Trial primary completion date • CNS Disorders • Hypotension • Movement Disorders • Multiple System Atrophy • Parkinson's Disease

Investigating the Therapeutic Role of Atomoxetine in Ministration of Rheumatoid Arthritis Pain (NeuPSIG 2025) - No abstract available

CNS Disorders • Musculoskeletal Pain • Pain

Acetazolamide plus Atomoxetine Changed Chemosensitivity in Obesity Hypoventilation Syndrome (ERS 2025) - No abstract available

Genetic Disorders • Obesity • Respiratory Diseases

Children and Adolescents with Co-Occurring Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder: A Systematic Review of Multimodal Interventions. (PubMed, J Clin Med) - "Specifically, methylphenidate (MPH, n = 11), atomoxetine (ATX, n = 11), guanfacina (n = 4), clonidine (n = 1), or atypical antipsychotics (n = 1) were examined. While limited data prevent definitive conclusions, MPH and ATX appear to be relatively safe and effective on hyperactivity-impulsivity symptoms, even in individuals with ASD. Evidence on non-pharmacological treatments is limited, and further studies are needed to better establish their therapeutic potential."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Psychiatry

Pharmacologic Reversal of Xylazine-Induced Unconsciousness in Rats. (PubMed, Anesth Analg) - "Atipamezole, d-amphetamine, and chloro-APB accelerate emergence from xylazine-induced unconsciousness and restore EEG oscillation patterns consistent with wakefulness. However, none of these reversal agents restore recognition memory."

Journal • Preclinical • CNS Disorders • Pain

The current state of PGx (gene-drug pairs) implementation in youth mental health. (CINP-AsCNP 2025) - "Sertraline (18%), fluvoxamine (9%), risperidone (8%), aripiprazole (7%), and atomoxetine (6%) were the most frequently prescribed psychotropic medications with a PGx-based dosing guideline...Our findings to date have: (1) demonstrated that delivery of PGx testing improves symptoms, reduces adverse drug effects, and decreased healthcare utilization; (2) identified novel associations between CYP2D6 genetic variation and the efficacy of fluoxetine and amphetamine treatment; and (3) estimated, for the first time, a high prevalence (46%) of phenoconversion in youth receiving pharmacotherapy for mental health conditions. Our findings suggest prescribing of psychotropic medications with available PGx-based guidelines is common among youth and approximately one in every 10 youth are taking psychotropic medications that are incongruent with their PGx profile. These results are facilitating the integration of Canada's first evidence-based genetic testing service to improve..."

Pediatrics • Psychiatry

New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Clinical efficacy, safety profiles, and advancements in technology-based interventions were analyzed. Stimulant medications, such as methylphenidate and amphetamines, remain the mainstay of ADHD treatment but pose risks of abuse and dependence. Non-stimulant options, including atomoxetine and extended-release α-2 agonists like guanfacine and clonidine, provide alternatives for patients who cannot tolerate stimulants. Emerging therapeutic devices, including the Monarch eTNS System and EndeavorRx, offer innovative drug-free treatment options. The prognosis for ADHD is variable, with some individuals experiencing symptom resolution while others continue to face lifelong challenges. A multidisciplinary approach that integrates pharmacotherapy, behavioral therapy, and novel technology-based interventions holds promise for improving patient outcomes and addressing the societal impact of ADHD."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

Medical management of ADHD in adults: part 2. (PubMed, Drug Ther Bull) - "Second-line treatments such as atomoxetine are also available for those who cannot tolerate or do not respond to methylphenidate or lisdexamfetamine. In the UK, ADHD has been previously managed largely in tertiary clinics, but many cases could be managed by appropriately trained clinicians in secondary or primary care (as already happens in some countries), with great benefit for patients and job satisfaction for clinicians."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Methylphenidate-Induced Stuttering in a Patient With Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: A Case Report. (PubMed, Clin Neuropharmacol) - "Despite that the relationship between MPH and stuttering is not well-documented, it is important to recognize that side effects may arise when initiating treatment or increasing the dosage. Typically, quitting the medication is sufficient to alleviate these side effects. Further studies are needed to better understand the side effects and mechanisms of action associated with MPH."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Psychiatry

Genitourinary Considerations for the Pharmacodynamics and Pharmacokinetics of Medications for Attention-Deficit Hyperactivity Disorder (APA 2025) - "Description We considered how genitourinary physiology may alter the effects of atomoxetine, methylphenidate, and amphetamine salts through pharmacodynamic and pharmacokinetic mechanisms. Pharmacokinetically, the genitourinary system may impact the rates of drug metabolism and should be considered when deciding appropriate doses of medications. Pharmacodynamically, these medications commonly prescribed for ADHD may cause rare but severe side effects due to the role of the sympathetic activity in the regulation of the genitourinary system."

PK/PD data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Dental Disorders • Fatigue • Overactive Bladder • Pain • Psychiatry • Urology • Xerostomia • CES1

The Combination of Pimavanserin and Atomoxetine Reduces Obstructive Sleep Apnea Severity: A Randomized Trial (ATS 2025) - "The combination of atomoxetine and pimavanserin significantly reduced OSA severity, lowering arousal index and overnight hypoxemia. Compared to placebo, the combination did not raise the risk of many adverse effects seen in similar trials (e.g., insomnia, headache, tachycardia), except for a mild heart rate increase. Pimavanserin shows promise to be associated to atomoxetine for treating OSA and merits further, larger trials."

Clinical • Cardiovascular • Insomnia • Obstructive Sleep Apnea • Pain • Respiratory Diseases • Sleep Disorder

Attention-Deficit/Hyperactivity Disorder Medication Use in Pregnancy and Risk of Preterm Birth: A Population-Based Cohort Study. (PubMed, Paediatr Perinat Epidemiol) - "ADHD medication may modestly increase the risk of preterm birth, especially with atomoxetine early and methylphenidate late in pregnancy, and with longer durations of use."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Recognition and treatment of attention deficit-hyperactivity disorder in patients with treatment-resistant burning mouth syndrome: a retrospective case study. (PubMed, Front Pain Res (Lausanne)) - "Algorithm-based pharmacotherapy using ADHD-effective medications (methylphenidate, atomoxetine, guanfacine, aripiprazole, venlafaxine, and duloxetine) was administered. ADHD is frequently comorbid in patients with treatment-resistant BMS, and ADHD-targeted pharmacotherapy may help alleviate pain, cognitive dysfunction, and brain perfusion abnormalities. These findings suggest that ADHD screening, diagnosis, and multidisciplinary management involving psychiatrists could play a crucial role in optimizing clinical outcomes in patients with BMS."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Depression • Developmental Disorders • Mood Disorders • Pain • Psychiatry

Adrenergic Modulation of Cortical Gain and Sensory Processing in the Mouse Visual Cortex. (PubMed, Brain Sci) - "Behaviorally, clonidine impaired accuracy at moderate noise levels, while atomoxetine reduced discrimination performance and increased response variability. Our findings demonstrate that NE regulates the balance between signal amplification and noise suppression in a noise- and context-dependent manner. These results extend existing models of neuromodulatory function by linking interlaminar communication and cortical variability to perceptual decision-making."

Journal • Preclinical

Dual-Responsive Ion-Exchange Resin Encapsulated Atomoxetine Hydrochloride for Taste-Masking and Biphasic Release. (PubMed, AAPS PharmSciTech) - "Notably, the plasma drug concentration of ATH ODT remained steadier than that of the commercial product when administered twice. In conclusion, ATH ODT represents a promising formulation that effectively masks bitter taste and provides biphasic release for the treatment of ADHD."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Astaxanthin Mitigates ADHD Symptoms in Spontaneously Hypertensive Rats via Dopaminergic Modulation and Brain-Gut Axis Regulation. (PubMed, Molecules) - "Spontaneously hypertensive rats (SHRs), widely used ADHD model animals, were treated with ASTA (50/100 mg/kg/day) for three weeks, 5 mg/kg/day atomoxetine (ATO) as the positive, and Wistar Kyoto (WKY) rats as control...Furthermore, cerebellar cells were protected, and the structure of the intestinal microbiota was regulated. ASTA can mitigate ADHD symptoms in SHR through the modulation of the dopaminergic system, multiple neurotransmitters, neurotrophic factors, and the neuro-intestinal environment, which establishes ASTA as a promising nutraceutical candidate for adjunctive therapy in pediatric ADHD."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Mood Disorders • Pediatrics • Psychiatry

Pharmacogenomic Implications of Genes on the American College of Medical Genetics Secondary Findings List (PAS 2025) - "In one case, a child with a pathogenic variant SDHA, associated with risk of pheochromocytoma, was prescribed atomoxetine for ADHD which may interfere with the annual screenings of metanephrine levels... Of the 81 genes reviewed, 30 (37%) had Level 1 or Level 2 interactions. PharmGKB identified 3/4 (75%) Level 1 interactions and 5/26 (19%) Level 2 interactions. GeneReviews identified 3/4 (75%) Level 1 interactions and 19/26 (73%) Level 2 interactions."

Biomarker • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Endocrine Cancer • Genetic Disorders • Oncology • Psychiatry • Solid Tumor • Ventricular Tachycardia • SDHA

Dopaminergic medications as a preventive for myopia: insights derived from pediatric patients diagnosed with attention deficit hyperactivity disorder. (PubMed, Postgrad Med J) - "Untreated ADHD in children is linked to a higher myopia risk than both non-ADHD individuals and treated ADHD patients. Dopaminergic treatments may provide a therapeutic avenue for mitigating myopia progression by enhancing dopamine signaling pathways. Key messages What is already known on this topic  Dopamine release in the retina inhibits myopia progression, and ADHD is linked to dopaminergic dysfunction. ADHD treatments like methylphenidate enhance dopamine signaling, but their effect on myopia risk has not been thoroughly studied. What this study adds  This study shows that untreated ADHD children have a higher risk of myopia, while dopaminergic treatments significantly reduce this risk. The use of multiple ADHD medications further strengthens the protective effect. How this study might affect research, practice or policy  These findings suggest that ADHD treatments may serve as a new approach for myopia prevention, encouraging cross-field research and..."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Ophthalmology • Pediatrics • Psychiatry

Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. (PubMed, Lancet Psychiatry) - "Practitioners should monitor blood pressure and pulse in patients with ADHD treated with any pharmacological intervention, and not stimulants only. Given the short duration of available randomised controlled trials, new research providing insights on the causal effects of ADHD medications on cardiovascular parameters in the longer term should be funded."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Psychiatry